Friedrichs K, Lohmann D, Höfler H
Department of Gynecology and Obstetrics, University of Hamburg, Medical School, Germany.
Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64(4):209-12. doi: 10.1007/BF02915114.
Amplification of genomic DNA encoding oncogenes such as HER-2 (syn.c-erbB2/c-neu) may be substantially involved in the initiation and progression of breast cancer. In order to refine and facilitate the quantitative analysis of HER-2 amplification in breast cancer, differential polymerase chain reaction (PCR) was performed on DNA derived from single cryosections of tumor tissue. This technique is based on the simultaneous amplification of a potentially amplified oncogene (HER-2) and a reference gene (IFN-gamma). Differential PCR yielded reproducible results that were in agreement with gene copy quantification using the dot blot technique. Thus we suggest differential PCR to be a reliable and rapid method for determining relative gene dosage in a minute amount of tumour tissue.
诸如HER-2（同义词：c-erbB2/c-neu）等致癌基因的基因组DNA扩增可能在乳腺癌的发生和发展中起重要作用。为了优化并便于对乳腺癌中HER-2扩增进行定量分析，对来自肿瘤组织单冷冻切片的DNA进行了差异聚合酶链反应（PCR）。该技术基于同时扩增潜在扩增的致癌基因（HER-2）和一个参照基因（IFN-γ）。差异PCR产生了可重复的结果，这些结果与使用斑点印迹技术进行的基因拷贝定量一致。因此，我们认为差异PCR是一种在微量肿瘤组织中确定相对基因剂量的可靠且快速的方法。
